MAYNE PHARMA GROUP LIMITED — Director's Dealing 2016

Dec 6, 2016

Appendix 3Y Change of Director’s Interest Notice

**Appendix

3Y**

Rule 3.19A.2

**Change

of Director’s Interest Notice**

_Information or documents not available now must be given to ASX as soon as available.

Information and documents given to ASX become ASX’s property and may be made public._

Introduced

30/09/01 Amended 01/01/11

Mayne Pharma Group Limited

ABN 76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Robinson
Date of last notice	7 July 2016

Part 1 -­‐ Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

disclosed in this part.
Direct or indirect interest	Indirect – BRAK Super Pty Ltd
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Controller of registered holder
Date of change	2 December 2016
No. of securities held prior to change	407,519
Class	Ordinary Shares
Number acquired	184,000
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and estimated	$298,080.00
valuation
No. of securities held after changeNature of change	591,519 On-market trade
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

**Part

2 – Change of director’s interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest related	N/A
prior to change
Note: Details are only required for a contract in relation to which the interest has
changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change	N/A

Part 3 –+Closed period
Were the interests in the securities or contracts	No
detailed above traded during a+closed period
whereprior written clearance was required?
If so, was prior written clearance provided to allow	N/A
the trade to proceed during this period?
If prior written clearance was provided, on what	N/A
date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011